| |
|
| |
|
| |
 |
| |
| Forthcoming events |
| On Thursday 7 October 2010, Duncan Curley will be speaking on “Developments In Patent Litigation Procedure and Cross-Jurisdictional Litigation Management Strategies” at C5’s Forum on Biotech Patenting in London. Please contact us for further information. |
| |
| On Wednesday, 27 October 2010, Amanda Easey, Garry Mills and Duncan Curley will be running a workshop on Protecting Product Innovation at SMi’s 11th Annual Conference on Nutraceuticals and Functional Foods in London. Please click on this link for further information or contact us for details. |
| |
| On Friday, 19 November 2010, Duncan Curley will be giving a UK caselaw update to the Annual Biotechnology Seminar of the Chartered Institute of Patent Attorneys (CIPA). Please contact us for further information. |
| |
| Previous events |
| On 15-16 April 2010, Duncan Curley spoke on the European Commission’s Pharmaceutical Sector Enquiry at the Academy of European Law’s Biennial Conference on European Pharmaceutical Law in Brussels. To download Duncan’s slides from the conference, please click here. |
| |
| On Tuesday 30 March 2010, Garry Mills spoke on “Costs in Lookalike Cases – is Europe a level playing field?” at a seminar at the British Institute of International and Comparative Law in London. To download Garry’s slides from the seminar, please click here. |
| |
| On 26 November 2009 Duncan Curley spoke on the European Commission’s Pharmaceutical Sector Enquiry at the Chartered Institute of Patent Attorney’s Annual Biotechnology Conference. To download Duncan’s slides from the conference, please click here |
| |
| On 19th October 2009 Duncan Curley spoke on “Development of biosimilar medicines – Intellectual Property Issues” at Visiongain’s 5th Annual Biosimilars conference in London. To download Duncan’s slides for the conference, please click here |
| |
| Workshop: Patent Issues in the Development of Biosimilar Medicines |
| We have devised a workshop briefing entitled Patent Issues in the Development of Biosimilar Medicines for those companies interested in developing follow-on biologics for the European market. The workshop covers the products erythropoietin, insulin and G-CSF. The workshop agenda is set out below. Innovate Legal will run this workshop briefing on request, either at our offices in central London or at the premises of your company. Please contact us by email or by telephone
(+ 44 (0)20 7936 9286) for further details |
| |
|
| SESSION ONE |
| An overview of the commercial and regulatory landscape |
| The first wave of biosimilar medicines |
| The second wave: 2010 and beyond |
| Patent law basics |
|
|
| SESSION two |
| Erythropoietin |
| Commercial overview |
| The Dynepo ® litigation |
| Lessons from the public record: Aranesp ® |
|
|
| SESSION three |
| Case Studies: insulin and G-CSF |
| Recombinant insulin: commercial overview |
| A closer look at insulin glargine |
| G-CSF: commercial overview |
| Lenograstim and PEGylated G-CSF (Neulasta ®) |
|
|
|
| |
|
| [ Site Map ] |
|
